Navigation Links
PRA Participates in Landmark Alzheimer's Prevention Clinical Trial
Date:7/24/2012

RALEIGH, N.C., July 24, 2012 /PRNewswire/ -- PRA, a leading Clinical Research Organization, announces that it is participating in a groundbreaking Alzheimer's disease study that could lead to treatments delaying or even preventing the emergence of symptoms in people destined to develop the disease because of their genetic background. The clinical trial is a collaborative effort involving the Banner Alzheimer's Institute (BAI); Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY); the University of Antioquia in Colombia; and the National Institutes of Health (NIH). 

The trial will include about 300 participants in Colombia, home to a kindred of nearly 5,000 people who share a rare genetic mutation that triggers Alzheimer's symptoms at an early age. A smaller number of individuals in the United States will also participate. The Phase IIa trial will utilize Genentech's investigational drug crenezumab. This humanized monoclonal antibody targets amyloid beta, a protein thought by many scientists to play a key role in the development of the disease.

"This study has the potential to change patients' lives by shifting the research paradigm in Alzheimer's from treatment to early prevention," said Kent Thoelke, PRA's Executive Vice President of Scientific and Medical Affairs. "PRA and its specialty neurosciences group are proud to be involved with this landmark program and to be working with leaders in the field of Alzheimer's research like Banner Alzheimer's Institute and Genentech."

The prevention trial was recently announced by BAI, Genentech and NIH at the unveiling of the National Plan to Address Alzheimer's Disease. The federal plan aims to develop effective treatment and prevention strategies by the year 2025 by increasing research funding, training health professionals and improving public-private partnerships.

About PRA
PRA is transforming clinical trials through our people, innovation and transparency. PRA provides personalized service customized to the unique requirements of each study. We support our global reach and innovative approach through flexible and reliable service, delivered by skilled employees dedicated to ensuring that sponsors achieve their long-term goals.

We serve our clients across all phases of pharmaceutical and biotech drug development by combining therapeutic and operational expertise with local knowledge. Offering services in 80+ countries and serving sponsors for 30+ years, we have amassed a level of expertise that has enabled us to work on a variety of compounds, ranging from niche treatments and therapies to blockbuster drugs. But at PRA, we are looking to the future, not the past. Our increasingly forward-thinking approach to transforming the clinical trial landscape will continue to make a difference to healthcare patients around the world.

To learn more about PRA, please visit praintl.com, email endpoints@praintl.com or call our Global Headquarters.



'/>"/>
SOURCE PRA
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Misonix Participates In Cleveland Spine Review
2. BlackStratus participates in Joint FDA-ISPE CGMP Conference
3. University of Michigans Wolverine Venture Fund Participates in $25 Million Series D Investment in Sonitus Medical
4. President Obama Signs Landmark Accessible Prescription Drug Label Bill
5. Mylan Applauds Signing of Landmark "Food and Drug Administration Safety and Innovation Act"
6. Landmark Sleep Apnea, Heart Failure Study Recruits 1,000th Participant
7. Asubio Initiates Landmark Clinical Study in Spinal Cord Injury
8. Berg Pharma launches clinical trial on BPM 31543 for prevention of chemotherapy-induced alopecia (CIA)
9. Joslin Diabetes Center Convenes Leaders in Diabetes Prevention, Treatment, Payment, Education and Research at Diabetes Innovation 2012
10. Inspiration Biopharmaceuticals Announces Clinical Hold of Clinical Trials Evaluating IB1001 for the Treatment and Prevention of Bleeding in Hemophilia B
11. Tethys Bioscience and Lose it! Announce a Strategic Partnership to Support Diabetes Prevention
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/6/2017)... , May 5, 2017   Provista , a proven ... than 200,000 customers, today announced Jim Cunniff as ... of executive and business experience to Provista, including most recently ... in California . He assumed his new ... is a great fit for Provista," says Jody Hatcher ...
(Date:5/4/2017)... Tenn. , May 4, 2017  A ... Infection Control, Ultraviolet-C light as a ... Tru-D SmartUVC,s ability to reduce bioburden on anesthesia ... bioburden reduction on high-touch, complex medical equipment surfaces ... surgical infections. "This study further validates ...
(Date:5/4/2017)... May 4, 2017  A new tight-tolerance microextrusion ... other highly-engineered materials, is being launched by Natvar, ... been developed in recent years to service a ... surgical applications. More expensive materials such as glass ... tubing due to their ability to consistently hold ...
Breaking Medicine Technology:
(Date:5/26/2017)... ... , ... Amir Qureshi, MD is the first physician in Arkansas to implant ... The Nuvectra™ Algovita SCS System has been FDA approved as a treatment option for ... to introduce the most powerful SCS system and the only stretchable lead on the ...
(Date:5/26/2017)... ... May 26, 2017 , ... A new analysis of community health data ... are located in the Midwest. With the average cost of healthcare rising and the ... with both the quality and affordability of where they live. An annual 2017 report ...
(Date:5/26/2017)... ... May 26, 2017 , ... via seating is proud to ... task chair specifically designed for clinical areas. Genie Copper Mesh is a crossover ... Cupron® to provide customers with a game changing chair that is affordably priced,” ...
(Date:5/26/2017)... ... ... After raising nearly $30,000 on Kickstarter , about three-times its original campaign ... crowdfunding price on Indiegogo . , “Along with creating an anti-stress gadget to ... fidget toy to the market that was made of superior quality and wouldn’t break ...
(Date:5/26/2017)... (PRWEB) , ... May 26, 2017 , ... Silver Birch ... community, which is located on more than four acres of land at 5620 Sohl ... , The 103,000 square-foot building includes 125 studio and one-bedroom apartments. Each of ...
Breaking Medicine News(10 mins):